VolitionRx Reports High Accuracy in Feline Cancer Blood Test, Unlocking $5M Milestone
VolitionRx's Nu.Q Vet prototype assay shows 97% specificity in detecting feline lymphoma, advancing a liquid biopsy for cats and unlocking a $5 million contractual milestone upon peer-reviewed publication.
VolitionRx Limited (NYSE American: VNRX) announced the submission for peer review of a clinical manuscript demonstrating high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The study achieved 97% specificity and identified 86% of lymphoma cases, marking a significant step toward developing a blood-based liquid biopsy test for feline cancer.
The company stated that the technology addresses a substantial unmet need in veterinary medicine. Companion animal oncology is a growing market, and a non-invasive blood test could transform early detection and monitoring of cancer in cats. According to the press release, the publication of this study in a peer-reviewed journal is expected to unlock a $5 million contractual milestone payment, underscoring the commercial potential of the assay.
VolitionRx is focused on advancing epigenetics-based diagnostics for both human and animal health. The Nu.Q platform detects nucleosomes associated with disease, enabling simple, cost-effective blood tests. The feline prototype assay is part of the company's broader strategy to expand into the companion animal market, which offers significant revenue opportunities through product commercialization and potential future milestone payments.
The implications of this development are twofold. First, it provides veterinarians with a highly specific tool to identify lymphoma, a common cancer in cats, potentially allowing earlier intervention and better outcomes. Second, the milestone payment validates VolitionRx's technology and business model, providing capital to further its pipeline. The company also sees this as a stepping stone for its human diagnostic programs, as the underlying epigenetic technology is applicable across species.
VolitionRx's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring.
For further information, visit the company's website at www.Volition.com. The full press release is available at https://ibn.fm/ARsEY.